Peptides / Immune and antimicrobial

Synthetic analog · 2 amino acids · 275.3 Da

Vilon (KE)

Vilon is a synthetic two-amino-acid peptide (Lys-Glu) from the Khavinson bioregulator family, and no approval as a drug was found. Its studies are in animals and lab cells, on the immune system, aging and tumor growth. PepBank shows 70 results on Vilon from animal and lab studies. No study in people has reported results yet. Data as of 2026-10-30.

Also known as KE, Lys-Glu, Vilon, Vilon peptide

2 amino acids, from first to lastKE

Evidence level: Animal and lab studies onlyNo study in people has results. ClinicalTrials.gov lists no trial.

Results in people

0% of 70 results

Results in animals

54% of 70 results

Results in lab cells

46% of 70 results

From computer models

0% of 70 results

Overview

Vilon (KE) at a glance

What it is	Synthetic analog, 2 amino acids
Approval	Regulatory status not recorded
In sport	Status unknown
Studies	22 studies with results. All of them gave Vilon, with 70 results. 38 in animals32 in lab cells
Clinical trials	None registered
Community use	Community interest in immune and cellular aging research

The science

What is Vilon?

Synthetic Lys-Glu peptide from the Khavinson bioregulator family.

Amino acids in one chain

Vilon (KE) structure and chemistry

The key facts about the molecule. Long codes are in the closed section below.

Sequence, 2 amino acidsFrom the first amino acid to the last

+K1−E

Darker means more water-repelling+ and − show charge in the body

Structure

Vilon (KE) is a synthetic analog of 2 amino acids, with no ring, no changed amino acids.

Formula

C₁₁H₂₁N₃O₅

Molecular weight

275.3 g/mol

CAS number

45234-02-4

Development

Highest phase: no known clinical development.

Identifiers

PubChem 7010502, ChEMBL CHEMBL365790, UNII H34V7IM5ML

Full sequence, SMILES and InChIKey

Three-letter sequence
H-Lys-Glu-OH

InChIKey
UGTZHPSKYRIGRJ-YUMQZZPRSA-N

SMILES
C(CCN)C[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)O)N

See charge, composition and 3D structure on the Scientific page

The evidence

What Vilon studies show

Results grouped by what the studies measured. Each card shows where its results come from.

Animal and lab studies onlyNo study in people has results. ClinicalTrials.gov lists no trial.

Cancer

16 results · 16 animal

In mice, Vilon increased mammary cancer incidence compared with control. International journal of cancer, 2002

Top results

In mice, Vilon increased mammary cancer incidence compared with control. (International journal of cancer, 2002)
In rats, bladder tumors developed in 56% of vilon-treated animals versus 75.5% of controls. (Bulletin of experimental biology and medicine, 2001)
In rats with transplanted tumors, Vilon increased tumor cell death compared with controls. (Advances in gerontology = Uspekhi gerontologii, 2004)

Immune system and inflammation

20 results · 4 animal · 16 lab

In rats, Vilon inhibited radiation-induced death of spleen immune cells. Bulletin of experimental biology and medicine, 2000

Top results

In rats, Vilon inhibited radiation-induced death of spleen immune cells. (Bulletin of experimental biology and medicine, 2000)
In rats with early chronic renal failure, Vilon decreased a blood growth factor. (Bulletin of experimental biology and medicine, 2005)
In rats, vilon inhibited shrinkage of the thymus. (Rossiiskii fiziologicheskii zhurnal imeni I.M. Sechenova, 2002)

Liver

3 results · 3 animal

In rats with cirrhosis, Vilon increased liver glucose-6-phosphatase activity, while untreated rats retained cirrhotic levels. Tsitologiia, 2000

Top results

In rats with cirrhosis, Vilon increased liver glucose-6-phosphatase activity, while untreated rats retained cirrhotic levels. (Tsitologiia, 2000)
In rats with cirrhosis, liver cells contained 4.7% more total protein after Vilon treatment than in untreated rats. (Tsitologiia, 2000)
In rats with cirrhosis, Vilon-treated liver cells had 11.5% higher ploidy levels than untreated cells. (Tsitologiia, 2000)

Cells, genes and aging

15 results · 2 animal · 13 lab

In rats, Vilon partly inhibited radiation-induced thymus aging. Advances in gerontology = Uspekhi gerontologii, 2002

Top results

In rats, Vilon partly inhibited radiation-induced thymus aging. (Advances in gerontology = Uspekhi gerontologii, 2002)
In cells, Vilon loosened total heterochromatin in cultured human lymphocytes. (Biogerontology, 2004)
In cells from the human thymus, KE increased mitochondrial staining during aging. (Advances in gerontology = Uspekhi gerontologii, 2020)

Sex hormones and fertility

2 results · 2 animal

In rats, Vilon affected LH, ACTH and brain neurotransmitter levels. The abstract did not report their directions. Advances in gerontology = Uspekhi gerontologii, 2006

Top results

In rats, Vilon affected LH, ACTH and brain neurotransmitter levels. The abstract did not report their directions. (Advances in gerontology = Uspekhi gerontologii, 2006)
In rats, blood prolactin decreased during Vilon treatment. (Advances in gerontology = Uspekhi gerontologii, 2006)

Stomach and gut

2 results · 2 animal

In rats, oral Vilon changed five digestive enzyme activities. The abstract did not give a direction for each enzyme. Bulletin of experimental biology and medicine, 2001

Top results

In rats, oral Vilon changed five digestive enzyme activities. The abstract did not give a direction for each enzyme. (Bulletin of experimental biology and medicine, 2001)
In rats, Vilon increased digestive enzyme activity most strongly in older animals and reduced differences between ages. (Bulletin of experimental biology and medicine, 2001)

All 22 Vilon studies by area Open the Scientific page

Key Vilon studies

Studies in people come first, then studies in animals and in the lab.

Animals
Inhibitory effect of the peptide epitalon on the development of spontaneous mammary tumors in HER-2/neu transgenic mice
Anisimov et al. 2002 · International journal of cancer · cited by 22
5 results
Animals
Effect of the dipeptide vilon on activity of digestive enzyme in rats of various ages
Khavinson et al. 2001 · Bulletin of experimental biology and medicine · cited by 4
2 results
Animals
Peptide bioregulators inhibit apoptosis
Khavinson et al. 2000 · Bulletin of experimental biology and medicine · cited by 2
2 results
Animals
Effect of peptide Vilon on the content of transforming growth factor-beta and permeability of microvessels during experimental chronic renal failure
Gavrisheva et al. 2005 · Bulletin of experimental biology and medicine · cited by 1
2 results
Animals
[Combined effect of vilon and cyclophosphane on tumor transplants and lymphoid tissue explants in mice and rats of various age]
Barykina et al. 2003 · Advances in gerontology = Uspekhi gerontologii · cited by 1
4 results

All 22 Vilon (KE) studies

Vilon clinical trials

ClinicalTrials.gov lists no trial of Vilon. A trial under another name may exist.

Status and safety

Is Vilon approved?

FDA

United States

Status unknown

Status unknown.

EMA

European Union

Status unknown

Status unknown.

WADA

Sport

Not recorded

Status unknown.

Regulatory status not recorded. Status unknown.

Laws and labels change, so check the regulator for the current status.

Vilon side effects and safety

PepBank has 12 safety results from studies of Vilon. None of them come from studies in people, so they do not show what happens in people.

Safety results from studies (12)

In mice, Vilon increased mammary cancer incidence compared with control. (International journal of cancer, 2002)
In mice, mammary tumor development did not differ between Vilon and control groups until nine months. (Voprosy onkologii, 2002)
In mice, tumors appeared sooner on average with Vilon than control. (International journal of cancer, 2002)
In mice, Vilon increased the total tumor count compared with control. (International journal of cancer, 2002)
In mice, one tumor occurred in fewer Vilon-treated animals than controls. (Voprosy onkologii, 2002)
In mice, multiple tumors occurred more often with Vilon than control. (Voprosy onkologii, 2002)
In mice, similar numbers developed lung metastases with Vilon and control. (Voprosy onkologii, 2002)
In mice, similar numbers developed lung metastases with Vilon and Epitalon. (Voprosy onkologii, 2002)
In mice, lung metastasis incidence was higher with Vilon than Epitalon. (Voprosy onkologii, 2002)
In mice, mammary tumor development did not differ between Vilon and Epitalon groups until nine months. (Voprosy onkologii, 2002)
In mice, one tumor occurred in fewer Vilon-treated animals than Epitalon-treated animals. (Voprosy onkologii, 2002)
In mice, multiple tumors occurred more often with Vilon than Epitalon. (Voprosy onkologii, 2002)

See every safety result on the Scientific page

Doses studied (8 shown)

The doses that these studies used. They are not recommendations.

Dose as reported	Class	Species	Route	Duration	Design	Source
1 microg/mouse	Animal	mouse	subcutaneous	Not reported	Study in live animals	Anisimov 2002
1 mg/kg	Animal	mouse	injection	Not reported	Study in live animals	Barykina 2003
50 microg per rat	Animal	rat	Not reported	Not reported	Study in live animals	Kudriavtseva 2006
0.5 mcg	Animal	rat	injection	Not reported	Study in live animals	Barykina 2004
1 meg	Animal	mouse	subcutaneous	Not reported	Study in live animals	Alimova 2002
1.7 micrograms/kg daily	Animal	rat	injection	5 days	Study in live animals	Kudriavtseva 2000
5 ng/ml	Lab	rat	Not reported	Not reported	Study on tissue taken from a body	Barykina 2003
20 ng/ml	Lab	rat	Not reported	Not reported	Study on tissue taken from a body	Kniaz'kin 2002

From the community

How people use it

What people report online. It comes from forums and guides, not from studies.

Community-reported. Not tested in trials.

The guide describes immune and cellular aging research. It reports a use pattern, without proof of safety or benefit.

Reported routines and cautions

What people use it for

Community interest in immune and cellular aging researchS1

Reported regimens

Regimens that community sources report for Vilon. Community-reported, not tested in trials.
Context	Route	Amount	How often	How long	Agreement	Sources
Community interest in immune and cellular aging research	subcutaneous injection	100 to 200 mcg per dose	once daily	10 to 20 days	Single non-vendor guide. The underlying community reports were not independently verified.	S1

Community sources

S1Vilon community guide (opens in a new tab)vialguide.com
S2About | Vial Guide (opens in a new tab)vialguide.com

Gaps

This is one secondary guide. It does not identify the underlying community reports. Other regimens exist in the guide. No official medicine label was established. Product purity and actual use were not independently tested.

Questions and more

Ask a question about Vilon

The answer links to every study it uses.

What does the evidence say about Vilon?Is Vilon tested in people?Compare with Vasoactive intestinal peptide (VIP, aviptadil)Compare with Thymosin alpha-1

Sources

Database: PepBank data for Vilon (data version 308560)
Regulator: FDA status record
Regulator: EMA status record
Regulator: WADA status record
Community: community sources (forums and guides), as summarized in the PepBank community file

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

PepBank is a research reference. Talk to a doctor before you use any peptide.

Ask your AI about Vilon

Curo is a peptide shop. PepBank and Curo have the same owner. See the Curo catalog (opens in a new tab).

Vilon (KE)

Also known as KE, Lys-Glu, Vilon, Vilon peptide

What it is

Synthetic analog, 2 amino acids

Approval

Regulatory status not recorded

In sport

Status unknown

Studies

22 studies with results. All of them gave Vilon, with 70 results.
38 in animals32 in lab cells

Clinical trials

None registered

Community use

Community interest in immune and cellular aging research

Dose as reported

Class

Species

Route

Duration

Design

Source

1 microg/mouse

Animal

mouse

subcutaneous

Not reported

Study in live animals

Anisimov 2002

1 mg/kg

Animal

mouse

injection

Not reported

Study in live animals

Barykina 2003

50 microg per rat

Animal

rat

Not reported

Study in live animals

Kudriavtseva 2006

0.5 mcg

Animal

rat

injection

Not reported

Study in live animals

Barykina 2004

1 meg

Animal

mouse

subcutaneous

Not reported

Study in live animals

Alimova 2002

1.7 micrograms/kg daily

Animal

rat

injection

5 days

Study in live animals

Kudriavtseva 2000

5 ng/ml

Lab

rat

Not reported

Study on tissue taken from a body

Barykina 2003

20 ng/ml

Lab

rat

Not reported

Study on tissue taken from a body

Kniaz'kin 2002

Context

Route

Amount

How often

How long

Agreement

Sources

Community interest in immune and cellular aging research

subcutaneous injection

100 to 200 mcg per dose

once daily

10 to 20 days

Single non-vendor guide. The underlying community reports were not independently verified.

Vilon (KE)

Vilon (KE) at a glance

What is Vilon?

Vilon (KE) structure and chemistry